The acute effects of glyceryl trinitrate (GTN) on exercise capacity in patients who have an implantable cardiac pump (LVAD) - Trial ANZCTR12623000116628
Access comprehensive clinical trial information for ANZCTR12623000116628 through Pure Global AI's free database. This Phase 2 trial is sponsored by St Vincent's Hospital Sydney and is currently Not yet recruiting. The study focuses on Heart failure.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Australian New Zealand Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
St Vincent's Hospital Sydney
MCS research trust fund (242058)
Timeline & Enrollment
Phase 2
Feb 13, 2023
Nov 01, 2024
Primary Outcome
Difference in peak VO2 between the cardiopulmonary tests with GTN and placebo, as assessed using a cardiometabolic cart ;; Distance completed during 6 minute walk test, measured in a corridor with a known distance
Summary
The goal of our study is to assess the effects of translingual GTN on exercise capacity as assessed by cardiopulmonary exercise testing (CPET) and 6-minute walk tests (6MWT), in LVAD recipients. GTN is a medication that relaxes the vessels and makes the work of the LVAD and the native heart easier. Additionally, this medication is cheap and readily available. Patients will perform 2 tests each (both CPET and 6MWT), one with a pre exercise dose of GTN and one with a dose of placebo. Patients and investigators will be blind to the treatment assigned to avoid biases. Our main hypothesis is that exercise capacity will be better with a pre exercise dose of GTN as compared to placebo. If this hypothesis is confirmed, GTN could potentially be used in rehabilitation programs for LVAD recipients.
ICD-10 Classifications
Data Source
Australian New Zealand Clinical Trials Registry
ANZCTR12623000116628
Non-Device Trial